This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Parkinson's disease
  • /
  • Safety and Efficacy of Focused Ultrasound Thalamot...

Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.

Read time: 1 mins
Published:1st Dec 2017
Author: Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB et al.
Source: JAMA Neurology
Availability: Pay for access, or by subscription
Ref.:JAMA Neurol. 2017;74(12):1412–1418.
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial

Clinical trials have confirmed the efficacy of focused ultrasound (FUS) thalamotomy in essential tremor, but its effectiveness and safety for managing tremor-dominant Parkinson disease (TDPD) is unknown.

Objective: To assess safety and efficacy at 12-month follow-up, accounting for placebo response, of unilateral FUS thalamotomy for patients with TDPD.

Design, Setting, and Participants: Of the 326 patients identified from an in-house database, 53 patients consented to be screened. Twenty-six were ineligible, and 27 were randomized (2:1) to FUS thalamotomy or a sham procedure at 2 centers from October 18th, 2012, to January 8th, 2015. The most common reasons for disqualification were withdrawal (8 persons [31%]), and not being medication refractory (8 persons [31%]). Data were analyzed using intention-to-treat analysis, and assessments were double-blinded through the primary outcome.

Interventions: Twenty patients were randomized to unilateral FUS thalamotomy, and 7 to sham procedure. The sham group was offered open-label treatment after unblinding.

Main Outcomes and Measures: The predefined primary outcomes were safety and difference in improvement between groups at 3 months in the on-medication treated hand tremor subscore from the Clinical Rating Scale for Tremor (CRST). Secondary outcomes included descriptive results of Unified Parkinson’s Disease Rating Scale (UPDRS) scores and quality of life measures.

Results: Of the 27 patients, 26 (96%) were male and the median age was 67.8 years (interquartile range [IQR], 62.1–73.8 years). On-medication median tremor scores improved 62% (IQR, 22%–79%) from a baseline of 17 points (IQR, 10.5–27.5) following FUS thalamotomy and 22% (IQR, -11%–29%) from a baseline of 23 points (IQR, 14.0–27.0) after sham procedures; the between-group difference was significant (Wilcoxon P = .04). On-medication median UPDRS motor scores improved 8 points (IQR, 0.5–11.0) from a baseline of 23 points (IQR, 15.5–34.0) following FUS thalamotomy and 1 point (IQR, -5.0–9.0) from a baseline of 25 points (IQR, 15.0–33.0) after sham procedures. Early in the study, heating of the internal capsule resulted in 2 cases (8%) of mild hemiparesis, which improved and prompted monitoring of an additional axis during magnetic resonance thermometry. Other persistent adverse events were orofacial paresthesia (4 events [20%]), finger paresthesia (1 event [5%]), and ataxia (1 event [5%]).

Conclusions and Relevance: Focused ultrasound thalamotomy for patients with TDPD demonstrated improvements in medication-refractory tremor by CRST assessments, even in the setting of a placebo response.

Trial Registration: identifier NCT01772693

Related study:
- ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease


Read abstract on library site

Access full article